Bausch + Lomb Corporation (NYSE:BLCO) Receives $15.56 Consensus Target Price from Analysts

Key Points

• Bausch + Lomb Corporation has a consensus rating of "Hold" from analysts, with one sell, seven hold, and three buy recommendations.
• The average 12-month price objective for Bausch + Lomb's stock is $15.56, reflecting analysts' expectations for future performance.
• CEO Brent L. Saunders increased his stake in the company by purchasing 22,000 shares at an average price of $11.28, demonstrating insider confidence in the business.

Shares of Bausch + Lomb Corporation (NYSE:BLCO - Get Free Report) have been assigned an average rating of "Hold" from the eleven brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $15.5556.

Several research firms recently commented on BLCO. Barclays cut their target price on shares of Bausch + Lomb from $19.00 to $16.00 and set an "equal weight" rating for the company in a research note on Monday, June 9th. Wells Fargo & Company upped their price objective on shares of Bausch + Lomb from $12.00 to $15.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. HC Wainwright raised their target price on shares of Bausch + Lomb from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Thursday, July 31st. Evercore ISI increased their price target on shares of Bausch + Lomb from $15.50 to $16.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Finally, Citigroup increased their price target on shares of Bausch + Lomb from $13.00 to $15.00 and gave the company a "neutral" rating in a report on Wednesday, July 9th.

Bausch + Lomb Stock Performance

BLCO traded up $0.1850 on Monday, hitting $14.6450. 255,515 shares of the company's stock were exchanged, compared to its average volume of 1,029,869. The firm has a market cap of $5.18 billion, a PE ratio of -18.78, a P/E/G ratio of 1.47 and a beta of 0.62. Bausch + Lomb has a twelve month low of $10.45 and a twelve month high of $21.69. The stock has a fifty day moving average of $13.48 and a two-hundred day moving average of $13.62. The company has a current ratio of 1.55, a quick ratio of 0.98 and a debt-to-equity ratio of 0.76.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.01. The firm had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.25 billion. Bausch + Lomb had a negative net margin of 5.58% and a positive return on equity of 2.33%. Bausch + Lomb's quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.13 earnings per share. Bausch + Lomb has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Bausch + Lomb will post 0.74 earnings per share for the current fiscal year.

Insider Activity at Bausch + Lomb

In other Bausch + Lomb news, CEO Brent L. Saunders purchased 22,000 shares of the stock in a transaction dated Thursday, May 22nd. The stock was bought at an average price of $11.28 per share, for a total transaction of $248,160.00. Following the transaction, the chief executive officer directly owned 719,156 shares in the company, valued at $8,112,079.68. This represents a 3.16% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 0.15% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bausch + Lomb

Several institutional investors and hedge funds have recently modified their holdings of BLCO. Trexquant Investment LP grew its holdings in shares of Bausch + Lomb by 5.8% during the 1st quarter. Trexquant Investment LP now owns 20,255 shares of the company's stock valued at $294,000 after purchasing an additional 1,108 shares during the last quarter. Woodline Partners LP grew its holdings in shares of Bausch + Lomb by 0.5% during the 1st quarter. Woodline Partners LP now owns 312,823 shares of the company's stock valued at $4,536,000 after purchasing an additional 1,436 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Bausch + Lomb by 58.5% during the 2nd quarter. Blue Trust Inc. now owns 4,502 shares of the company's stock valued at $59,000 after purchasing an additional 1,662 shares during the last quarter. Ridgewood Investments LLC bought a new stake in shares of Bausch + Lomb during the 2nd quarter valued at approximately $26,000. Finally, Gabelli Funds LLC grew its holdings in shares of Bausch + Lomb by 0.5% during the 2nd quarter. Gabelli Funds LLC now owns 444,000 shares of the company's stock valued at $5,776,000 after purchasing an additional 2,000 shares during the last quarter. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.